HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,647,197 | +19.0% | 43,120 | +12.3% | 0.00% | 0.0% |
| Q2 2023 | $1,384,451 | +19.8% | 38,382 | +26.8% | 0.00% | 0.0% |
| Q1 2023 | $1,155,935 | +2.7% | 30,268 | +53.0% | 0.00% | 0.0% |
| Q4 2022 | $1,125,823 | +91.5% | 19,786 | +33.0% | 0.00% | 0.0% |
| Q3 2022 | $588,000 | -19.0% | 14,882 | -9.8% | 0.00% | 0.0% |
| Q2 2022 | $726,000 | +25.8% | 16,497 | +14.1% | 0.00% | – |
| Q1 2022 | $577,000 | -41.7% | 14,456 | -41.2% | 0.00% | -100.0% |
| Q4 2021 | $989,000 | +40.5% | 24,589 | +42.0% | 0.00% | 0.0% |
| Q3 2021 | $704,000 | -11.7% | 17,318 | -1.4% | 0.00% | 0.0% |
| Q2 2021 | $797,000 | +23.6% | 17,556 | +13.4% | 0.00% | 0.0% |
| Q1 2021 | $645,000 | +44.0% | 15,476 | +47.6% | 0.00% | 0.0% |
| Q4 2020 | $448,000 | +70.3% | 10,486 | +4.8% | 0.00% | – |
| Q3 2020 | $263,000 | -74.0% | 10,002 | -73.5% | 0.00% | -100.0% |
| Q2 2020 | $1,010,000 | – | 37,676 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |